title: Therapeutic Value of an Integrin Antagonist in Prostate Cancer.
abstract: In recent decades we have seen an exponential interest in the implications of integrin receptors in cancer biology and especially in prostate tumour development. Integrins has been reported to control multiple mechanisms, such as cell survival, proliferation, differentiation, and migration. Here, we report the current understanding of the integrin signalling mechanisms in metastatic prostate tumour development, cross-talks between the primary and metastatic sites on tumour growth, interactions between tumour cells and tissue microenvironment, and epithelial-mesenchymal transition (EMT). Finally, this review presents the integrin-based chemotherapeutic agents currently under clinically consideration and provides an insight into cancer drug development using integrin as a target.
authors.affiliation: Galapagos SASU. 102, Avenue Gaston Roussel, 93230 Romainville, France. Philippe.Clement-Lacroix@glpg.com.
authors.forename: Clément-Lacroix
authors.initials: CL
authors.lastname: Philippe
mesh_terms: D000970:Antineoplastic Agents / Q000494:pharmacology* / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D058750:Epithelial-Mesenchymal Transition / Q000187:drug effects; D006801:Humans; D016023:Integrins / Q000037:antagonists & inhibitors*; D008297:Male; D058990:Molecular Targeted Therapy; D009362:Neoplasm Metastasis; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000378:metabolism; D015398:Signal Transduction / Q000187:drug effects; D059016:Tumor Microenvironment / Q000187:drug effects
chemical_list: D000970:Antineoplastic Agents; D016023:Integrins